Jay David Caplan Sells 64,197 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $158,566.59. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at approximately $379,253.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jay David Caplan also recently made the following trade(s):

• On Thursday, September 12th, Jay David Caplan sold 65,000 shares of Fractyl Health stock. The shares were sold at an average price of $2.90, for a total value of $188,500.00.

Fractyl Health Price Performance

NASDAQ GUTS traded down $0.06 on Wednesday, hitting $2.37. The company had a trading volume of 375,016 shares, compared to its average volume of 318,194. The company’s fifty day moving average price is $2.63 and its 200-day moving average price is $4.05. Fractyl Health, Inc. has a 12-month low of $1.74 and a 12-month high of $14.50. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.46 and a quick ratio of 7.46. The company has a market capitalization of $113.59 million and a PE ratio of -0.19.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million for the quarter. As a group, analysts predict that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Fractyl Health

Several large investors have recently made changes to their positions in GUTS. Rhumbline Advisers bought a new position in shares of Fractyl Health in the second quarter valued at $32,000. SG Americas Securities LLC bought a new stake in Fractyl Health in the 3rd quarter valued at about $33,000. Renaissance Technologies LLC bought a new position in Fractyl Health in the second quarter valued at $61,000. Beta Wealth Group Inc. bought a new stake in shares of Fractyl Health in the third quarter worth about $44,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after acquiring an additional 7,397 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.